Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood

Scottá, Marcelo Comerlato; Stein, Renato T.

doi:10.1016/j.jped.2022.10.004

Cited by 10 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, IN-delivered LAVs offer several advantages over IM-administered vaccines, being easy to use, noninvasive, and more adapted for mass vaccination. About dozen of LAV candidates against RSV are currently in clinical development and four of them have progressed to phase 2 evaluation 30,31 . Attenuation was achieved by deletion or modi cation of the NS2, SH, G, or M2-2 genes, and/or inserting temperature sensitivity mutations in the L gene 30,[32][33][34][35][36][37] .…”

Section: Introductionmentioning

confidence: 99%

New mucosal bivalent live-attenuated vaccine is protective against Human Metapneumovirus and Respiratory Syncytial Virus

Dubois,

Ogonczyk-Makowska,

Vacher

et al. 2023

Preprint

View full text Add to dashboard Cite

Live-Attenuated Vaccines (LAVs) stimulate robust mucosal and cellular responses and have the potential to protect against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV), the main etiologic agents of viral bronchiolitis and pneumonia in children. We inserted the RSV-F gene into an HMPV-based LAV (Metavac®) we previously validated for the protection of mice against HMPV challenge, and rescued a replicative recombinant virus (Metavac®-RSV), exposing both RSV- and HMPV-F proteins at its surface and expressing them in reconstructed human airway epithelium models. When administrated to BALB/c mice by the intranasal route, bivalent Metavac®-RSV demonstrated its capacity to replicate with reduced lung inflammatory score and to protect against both RSV and lethal HMPV challenges in vaccinated mice while inducing strong IgG and broad RSV and HMPV neutralizing antibody responses. Altogether, our results showed the versatility of the Metavac® platform and suggested that Metavac®-RSV is a promising mucosal bivalent LAV candidate to prevent pneumovirus-induced diseases.

show abstract